A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 09 Sep 2019 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2016 Status changed from recruiting to active, no longer recruiting.